BOSTON, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PHARE BIO INC, founded in 2020, is a community nonprofit in the Medical Research sector that reported $5.5M in total revenue in fiscal year 2024. Revenue surged 155% from the prior year, signaling strong growth momentum. Expenses of $4.8M left a modest 13% surplus.
PHARE BIO'S MISSION IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. USING NOVEL AI AND DEEP LEARNING APPROACHES, PHARE BIO AIMS TO RAPIDLY DISCOVER AND DEVELOP NEW CLASSES OF ANTIBIOTICS AGAINST THE DEADLIEST PATHOGENS, AND ENSURE THAT THESE THERAPIES REACH THE PATIENTS IN GREATEST NEED.
PHARE BIO'S PROGRAM MANDATE IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. PHARE BIO HAS A NUMBER OF PROMISING EARLY-STAGE PIPELINE PROJECTS AND IS...
PHARE BIO'S PROGRAM MANDATE IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. PHARE BIO HAS A NUMBER OF PROMISING EARLY-STAGE PIPELINE PROJECTS AND IS CONDUCTING EXTENSIVE IN VITRO AND IN VIVO DRUG DEVELOPMENT STUDIES TO ADVANCE POTENTIAL ANTIBIOTICS THROUGH THE RESEARCH AND DEVELOPMENT PROCESS. THESE ANTIBIOTIC CANDIDATES ARE DISCOVERED USING NOVEL AI/DEEP LEARNING METHODOLOGIES PIONEERED BY PROFESSOR JIM COLLINS' LAB AT MIT (PHARE BIO'S CO-FOUNDER), AND ARE DEVELOPED AND OPTIMIZED BY PHARE BIO FOR FUTURE CLINICAL APPLICATION. WITH THIS CUTTING-EDGE PLATFORM AND A NONPROFIT BUSINESS MODEL, PHARE BIO IS DEVELOPING NEW CLASSES OF ANTIBIOTICS AND UNIQUELY ADDRESSING ECONOMIC CHALLENGES FACING THE ANTIBIOTIC MARKET. IN THIS PAST YEAR, PHARE BIO DISCOVERED AND STUDIED ADDITIONAL NOVEL ANTIBIOTICS WITH ITS GENERATIVE AI DRUG DESIGN PLATFORM, FURTHER ADVANCING ITS EARLY-STAGE PIPELINE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $5,476,072 | $2,148,132 | +1.5% |
| Expenses | $4,787,029 | $1,461,003 | +2.3% |
| Net Income | $689,043 | $687,129 | +0.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| AKHILA KOSARAJU | CEO & PRESIDENT | 40.00 |
Officer
Director
|
$584,833 | $23,055 | $607,888 |
| WILLIAM FOSTER | CHAIR & TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| STEVE ELLIS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JAMES COLLINS | DIRECTOR (UNTIL 12/24) | 1.00 |
Director
|
$0 | $0 | $0 |
| JOSE-CARLOS GUTTIEREZ-RAMOS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT PLENGE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SUSAN URAHN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SETH BERKELY | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LEANNE MINALL | HEAD OF SCIENCE | 40.00 |
Highest
|
$158,125 | $4,069 | $162,194 |
| CLAIRE NISHIOKA ROBINSON | SENIOR DIRECTOR, BUSINESS STRATEGIES | 40.00 |
Highest
|
$243,333 | $12,105 | $255,438 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $5,476,072 | $4,787,029 | $7,089,770 | $689,043 |
| 2024 | $2,148,132 | $1,461,003 | $2,586,256 | $687,129 |
| 2023 | $2,009,513 | $1,249,510 | $1,837,494 | $760,003 |
| 2022 | $1,558,823 | $1,178,664 | $1,009,435 | $380,159 |
| 2021 | $1,057,242 | $453,432 | $632,271 | $603,810 |
Compare PHARE BIO INC with other nonprofits in Massachusetts and across the country.